Therapy refractory angioimmunoblastic T‐cell lymphoma in complete remission with lenalidomide

Abstract The prognosis of therapy refractory angioimmunoblastic lymphoma ( AITL ) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy. He was treated with lenalidomide 15 mg continuously and prednisone. After 2 yr follow‐up, the patient has no detectable disease. Lenalidomide was well tolerated without side‐effects. Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL .